Skip to main content
. 2019 Jul 22;9:10572. doi: 10.1038/s41598-019-46819-z

Figure 5.

Figure 5

Kaplan-Meier survival curve illustrating no difference in survival in patients with differing expression of DTYMK (median OS, 29.8 months vs. 40.3 months for low and high expressions respectively, HR 0.846, 95% CI 0.345–2.077, p = 0.715). Low and high immunoreactivity scores were 0–3 and 4–9, respectively.